SDAI Ltd. reported its unaudited condensed interim financial statements for the full year ended 31 December 2025. Cash and cash equivalents at the end of the period stood at USD 0.72 million. The company generated USD 2.06 million in net cash from financing activities for the twelve-month period. During the year, SDAI Ltd. expanded into the biotechnology sector with the incorporation of Beijing Blue Code Biotechnology Co., Limited, which was subsequently relocated and renamed Hainan Blue Code Biotechnology Co., Ltd. to optimize tax efficiency. The reported figures have not been audited or reviewed by the independent auditor.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SDAI Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: 7AG5V1L542OFLQ23) on February 16, 2026, and is solely responsible for the information contained therein.